[1] Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the Anemia of End-Stage Renal Disease with Crecombinant Human Erythropoietin: Results of a Combined Phase I and II Clinical Trial. New England Journal of Medicine, 316, 73-78.
http://dx.doi.org/10.1056/NEJM198701083160203
[2] Gotloib, L., Silverberg, D., Fudin, R. and Shostak, A. (2006) Iron Deficiency Is a Common Cause of Anemia in Chronic Kidney Disease and Can Often Be Corrected with Intravenous Iron. Journal of Nephrology, 19, 161.
[3] AMAG Pharmaceuticals, Inc. (2009) Feraheme (Ferumoxytol) Package Insert. Lexington.
[4] Balakrishnan, V.S., Rao, M., Kausz, A.T., et al. (2009) Physicochemical Properties of Ferumoxytol, a New Intravenous Iron Preparation. European Journal of Clinical Investment, 39, 489-496.
http://dx.doi.org/10.1111/j.1365-2362.2009.02130.x
[5] Iain, C.M., et al. (2014) A Randomized Comparison of Ferumoxytol and Iron Sucrose for Treating Iron Deficiency Anemia in Patients with CKD CJASN ePress.
http://dx.doi.org/10.2215/CJN.05320513